3597-21-5

Usage

Uses

Used in Oncology:
2-chloro-N-(2-chloroethyl)-N-(4-methylbenzyl)ethanamine is used as an antineoplastic agent for the treatment of various malignancies such as Hodgkin's disease and non-Hodgkin's lymphomas. It functions by alkyating and damaging the DNA of cancer cells, which inhibits their growth and division, leading to the destruction of these cells.
Used in Cancer Chemotherapy:
In the field of cancer chemotherapy, 2-chloro-N-(2-chloroethyl)-N-(4-methylbenzyl)ethanamine is used as a component of certain chemotherapy regimens. Its alkylating properties allow it to target and destroy cancer cells, contributing to the overall effectiveness of the treatment plan.
Used in Immunosuppression:
2-chloro-N-(2-chloroethyl)-N-(4-methylbenzyl)ethanamine is also used as an immunosuppressive agent. Its ability to suppress the immune system can be beneficial in certain medical scenarios where a reduction in immune response is required, such as in the treatment of autoimmune diseases or in organ transplantation to prevent rejection.

Downstream Products

• 212770-64-4 4-(4-methoxy-benzenesulfonyl)-1-(4-methyl-benzyl)-piperidine-4-carboxylic acid ethyl ester 
• 239797-70-7 [4-(4-chlorobenzyloxy)benzenesulfonyl]-1-(4-methylbenzyl)piperidine-4-carboxylic acid ethyl ester 
• 212770-65-5 4-(4-methoxy-benzenesulfonyl)-1-(4-methyl-benzyl)-piperidine-4-carboxylic acid 
• 239797-71-8 [4-(4-chlorobenzyloxy)benzenesulfonyl]-1-(4-methylbenzyl)piperidine-4-carboxylic acid 

Relevant academic research and scientific papers

Synthesis and structure - Activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis

The matrix metalloproteinases (MMPs) are a family of zinc-containing endopeptidases that play a key role in both physiological and pathological tissue degradation. In our preceding paper, we have reported on a series of novel and orally active N-hydroxy-α-phenylsulfonylacetamide derivatives. However, these compounds had two drawbacks (moderate selectivity and chirality issues). To circumvent these two problems, a series of novel and orally active N-substituted 4-benzenesulfonylpiperidine-4-carboxylic acid hydroxyamide derivatives have been synthesized. The present paper deals with the synthesis and SAR of these compounds. Among the several compounds synthesized, derivative 55 turned out to be a potent, selective, and an orally active MMP inhibitor in the clinically relevant advanced rabbit osteoarthritis model. Detailed pharmacokinetics and metabolism data are described.